Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

ErbB2/Her2 Antikörper (AA 1242-1255)

ErbB2/Her2 Reaktivität: Human WB, IHC (p), IP, IHC (fro) Wirt: Maus Monoclonal 3B5 unconjugated
Produktnummer ABIN967459
  • Target Alle ErbB2/Her2 Antikörper anzeigen
    ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))
    Bindungsspezifität
    • 32
    • 29
    • 27
    • 26
    • 25
    • 23
    • 23
    • 21
    • 16
    • 15
    • 13
    • 13
    • 10
    • 10
    • 9
    • 9
    • 9
    • 9
    • 8
    • 8
    • 8
    • 7
    • 7
    • 7
    • 7
    • 7
    • 7
    • 7
    • 7
    • 7
    • 7
    • 7
    • 6
    • 6
    • 5
    • 5
    • 5
    • 5
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    AA 1242-1255
    Reaktivität
    • 512
    • 187
    • 164
    • 34
    • 10
    • 7
    • 5
    • 4
    • 3
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Human
    Wirt
    • 404
    • 155
    • 11
    • 5
    • 3
    • 3
    Maus
    Klonalität
    • 407
    • 171
    • 2
    Monoklonal
    Konjugat
    • 268
    • 45
    • 37
    • 28
    • 24
    • 23
    • 17
    • 17
    • 16
    • 16
    • 15
    • 15
    • 8
    • 8
    • 8
    • 8
    • 8
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 1
    • 1
    Dieser ErbB2/Her2 Antikörper ist unkonjugiert
    Applikation
    • 294
    • 224
    • 139
    • 100
    • 95
    • 93
    • 87
    • 80
    • 66
    • 52
    • 28
    • 21
    • 12
    • 9
    • 8
    • 7
    • 5
    • 4
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunoprecipitation (IP), Immunohistochemistry (Frozen Sections) (IHC (fro))
    Marke
    BD Pharmingen™
    Produktmerkmale
    1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
    2. Please refer to us for technical protocols.
    3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
    Aufreinigung
    The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
    Immunogen
    Human c-erbB-2 aa. 1242-1255
    Klon
    3B5
    Isotyp
    IgG1
    Top Product
    Discover our top product ErbB2/Her2 Primärantikörper
  • Applikationshinweise
    Applications include immunoprecipitation (1-2 µg/one million cells), western blot analysis (1-2 µg/ml), and immunohistochemistry of frozen and formalin-fixed paraffin-embedded tissue sections (5-20 µg/ml). Positive control cell lines include MCF7 cells (ATCC HTB 22) and SK-BR-3 (ATCC HTB 30) human breast carcinoma cells.
    Kommentare

    Related Products: ABIN968585, ABIN967389

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    0.5 mg/mL
    Buffer
    Aqueous buffered solution containing ≤0.09 % sodium azide.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C
    Informationen zur Lagerung
    Store undiluted at 4°C.
  • Carraway, Cantley: "A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling." in: Cell, Vol. 78, Issue 1, pp. 5-8, (1994) (PubMed).

    Martinazzi, Crivelli, Zampatti, Martinazzi: "Relationships between epidermal growth factor receptor (EGF-R) and other predictors of prognosis in breast carcinomas. An immunohistochemical study." in: Pathologica, Vol. 85, Issue 1100, pp. 637-44, (1994) (PubMed).

    Penault-Llorca, Adelaïde, Houvenaeghel, Hassoun, Birnbaum, Jacquemier: "Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation." in: The Journal of pathology, Vol. 173, Issue 1, pp. 65-75, (1994) (PubMed).

    Schwechheimer, Läufle, Schmahl, Knödlseder, Fischer, Höfler: "Expression of neu/c-erbB-2 in human brain tumors." in: Human pathology, Vol. 25, Issue 8, pp. 772-80, (1994) (PubMed).

    Singleton, Niehans, Gu, Litz, Hagen, Qiu, Kiang, Strickler: "Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry." in: Human pathology, Vol. 23, Issue 10, pp. 1141-50, (1992) (PubMed).

    Zhau, Zhang, von Eschenbach, Scorsone, Babaian, Ro, Hung: "Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer." in: Molecular carcinogenesis, Vol. 3, Issue 5, pp. 254-7, (1991) (PubMed).

    van de Vijver, Peterse, Mooi, Wisman, Lomans, Dalesio, Nusse: "Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer." in: The New England journal of medicine, Vol. 319, Issue 19, pp. 1239-45, (1988) (PubMed).

  • Target
    ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))
    Andere Bezeichnung
    c-erbB-2 (ErbB2/Her2 Produkte)
    Synonyme
    CD340 antikoerper, HER-2 antikoerper, HER-2/neu antikoerper, HER2 antikoerper, MLN 19 antikoerper, NEU antikoerper, NGL antikoerper, TKR1 antikoerper, Erbb-2 antikoerper, Neu antikoerper, c-erbB2 antikoerper, c-neu antikoerper, mKIAA3023 antikoerper, wu:fv70f10 antikoerper, zgc:63601 antikoerper, erb2 antikoerper, erb-b2 receptor tyrosine kinase 2 antikoerper, ERBB2 antikoerper, Erbb2 antikoerper, erbb2 antikoerper
    Hintergrund
    C-erbB-2 (also known as HER2/neu), a 185 kDa transmembrane glycoprotein, is a member of the type 1 growth factor receptor subfamily which also includes c-erbB-3, c-erbB-4 and the epidermal growth factor receptor (EGFR), also known as c-erbB-1. Members of this receptor subfamily mediate the proliferation and differentiation of normal cells. They have a common structure consisting of an extracellular domain, a transmembrane region, and a cytoplasmic sequence. The extracellular regions contain two cysteine-rich domains, and the intracellular regions have sequence homology to known tyrosine kinases. C-erbB-2 reactivity has been detected in proximal kidney tubules, mucosal epithelium in the gastrointestinal tract, and squamous epithelium in skin. Most normal adult tissues show little or no reactivity with antibodies against c-erbB-2. However, c-erbB-2 is overexpressed in many human breast, stomach, ovary and bladder carcinomas. EGFR, c-erbB-3 and c-erbB-4 are also overexpressed in various human tumor cells, and it is thought that aberrant activation of type 1 growth factor kinase activities may contribute to tumor progression. The antibody 3B5 recognizes human c-erbB-2. A synthetic peptide corresponding to amino acids 1242-1255 (TAENPEYLGLDVPV) in the C-terminal domain of human c-erbB-2 was used as immunogen.
    Pathways
    RTK Signalweg, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Skeletal Muscle Fiber Development
Sie sind hier:
Kundenservice